Named Bioactive Compounds · Compound
Gossypol
Moderate Evidencesesquiterpenoid2 PubMed Studies
Hermetica Superfood Encyclopedia
Gossypol is a sesquiterpenoid compound extracted from cottonseed that exhibits cytotoxic properties primarily through mitochondrial dysfunction and apoptosis induction. Research has focused on its potential antifertility and anticancer mechanisms, though clinical evidence remains limited.
Gossypol is a polyphenolic sesquiterpene aldehyde naturally occurring in the pigment glands of cottonseed from cotton plants (Gossypium species). It is extracted from defatted cottonseed meal using solvent-based methods, typically employing butanol-ethanol-water mixtures or liquid acetone, with optimized conditions achieving up to 91% yield.
The research dossier explicitly states that search results lack details on key human clinical trials, RCTs, or meta-analyses for gossypol. No PubMed PMIDs for clinical studies are provided, with only one vague reference to Chinese clinical experiments without specific study parameters or outcomes.
No clinically studied dosage ranges are available in the research literature. The studies focus exclusively on extraction optimization rather than therapeutic dosing, with no standardization levels reported for clinical contexts. Consult a healthcare provider before starting any new supplement.
Gossypol is a polyphenolic binaphthyl dialdehyde (C₃₀H₃₀O₈, MW ~518.55 g/mol) found primarily in the pigment glands of cottonseed (Gossypium spp.). It is not a nutrient but a bioactive secondary plant metabolite with significant toxicological properties. Key characteristics: • Exists as two atropisomers: (+)-gossypol and (−)-gossypol, with the (−)-enantiomer exhibiting greater biological activity and toxicity. • Typical concentration in whole cottonseed: 0.4–1.2% of seed dry weight (4,000–12,000 mg/kg); glandless cotton varieties contain <0.01%. • In crude cottonseed oil (unrefined): approximately 0.1–0.6% gossypol; properly refined cottonseed oil contains negligible free gossypol (<0.01%). • Free gossypol (biologically active/toxic form) vs. bound gossypol (complexed with proteins/amino acids, particularly lysine, via Schiff base reactions during processing — largely biologically inert). • Contains six hydroxyl groups and two aldehyde groups responsible for its reactivity with amino acids (especially lysine, arginine), reducing protein bioavailability when present in cottonseed meal. • Binds metal ions (Fe²⁺, Zn²⁺, Ca²⁺), potentially acting as a chelator and impairing mineral bioavailability. • No vitamins, fiber, or macronutrient contribution — it is an antinutritional/toxic factor rather than a nutrient. • Lipophilic compound with moderate oral bioavailability; absorption occurs in the gastrointestinal tract, with hepatic accumulation noted. • FDA regulatory limit for free gossypol in human food-grade cottonseed products: ≤450 ppm (0.045%) in edible cottonseed flour. • WHO/FAO recommended maximum free gossypol in cottonseed meal for animal feed: 100–600 ppm depending on species. • Notable bioactive properties studied in vitro: aldehyde-mediated protein cross-linking, inhibition of lactate dehydrogenase and other dehydrogenases, and disruption of mitochondrial electron transport — these underpin its antispermatogenic activity (investigated as male contraceptive at 10–20 mg/day doses in Chinese clinical studies) but also its systemic toxicity (hypokalemia, cardiac toxicity, hepatotoxicity at chronic doses). • Bioavailability is influenced by dietary protein content (high protein diets increase gossypol binding and reduce free gossypol absorption) and by iron status (gossypol–iron complexes are poorly absorbed).
Gossypol exerts its biological effects primarily through disruption of mitochondrial function and induction of apoptotic pathways in cells. The compound interferes with sperm motility and viability by affecting mitochondrial energy production. Additionally, gossypol demonstrates cytotoxic activity against certain cancer cell lines through oxidative stress mechanisms and protein synthesis inhibition.
Clinical evidence for gossypol remains extremely limited with no documented randomized controlled trials demonstrating therapeutic benefits. Some Chinese clinical experiments reported 'quite satisfactory' results, but specific study designs, sample sizes, and quantified outcomes were not provided. The research dossier contains no human clinical trials meeting modern scientific standards. Current evidence is insufficient to support any clinical health benefits or therapeutic applications.
Gossypol has demonstrated significant safety concerns including potential reproductive toxicity and cytotoxic effects. The compound may cause decreased sperm count and motility, making it contraindicated for men attempting conception. Gossypol can induce oxidative stress and cellular damage at higher concentrations. Pregnant and breastfeeding women should avoid gossypol due to potential teratogenic effects and lack of safety data.
